Sanara MedTech (SMTI) Cash from Financing Activities (2010 - 2026)

Sanara MedTech has reported Cash from Financing Activities for 15 years, with the latest figure at -$475219.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 103.96% year-over-year to -$475219.0; the trailing twelve-month figure through Mar 2026 stood at -$3.6 million (down 111.91% YoY), and the FY2025 full-year result was $8.9 million, down 48.82% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$475219.0, down from $139427.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $14.4 million in Q3 2024, with the low at -$2.5 million in Q2 2025.
• Historically, Cash from Financing Activities has averaged $2.2 million across 5 years, with a median of -$144409.5 in 2022.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities tumbled 787.6% — and 2025, when it soared 1919.73%.
• Sanara MedTech's Cash from Financing Activities stood at -$304415.0 in 2022, then soared by 38.94% to -$185888.0 in 2023, then plunged by 546.06% to -$1.2 million in 2024, then soared by 111.61% to $139427.0 in 2025, then plunged by 440.84% to -$475219.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$475219.0 (Q1 2026), $139427.0 (Q4 2025), and -$774749.0 (Q3 2025), per Business Quant data.